Peptides DB

Research-centric peptide and protocol reference hub

Thymosin Alpha-1

Research-centric overview

Share
Peptide

### Thymosin Alpha-1 Summary Thymosin Alpha-1 (Tα1) is a peptide that plays a crucial role in modulating immune responses and has been investigated for its potential therapeutic applications in various conditions, including infections and inflammatory diseases.

Community effect votes, structured logs, and side-effect summaries.

Effect profile (overview)

Aggregate AI baseline blended with community voting. Hover to inspect effect strengths per category.

Effect profile (AI + community): Healing & recovery 4.0/5 · Inflammation & immune 4.0/5Healing 4.0Muscle 0.0Metabolic 0.0Neuro 0.0Sleep 0.0Inflammation 4.0Skin 0.0

Effect scores blend an AI baseline with community votes. Open the full chart to see sliders and vote on each category.

Research log summary heatmap

Compact view of how logs describe shifts in pain, sleep, and performance (−5 to +5). Treat this as qualitative, anonymous signal only.

No community research logs yet. When structured logs are added, this panel will summarize typical shifts in pain, sleep, and performance.

Anonymous side-effect patterns

Rough heatmap of anonymous side-effect and positive-signal tags — a "most-mentioned" snapshot, not safety or efficacy advice.

No anonymous side-effect reports yet. When reports are submitted, this panel will show a simple heatmap of tags like "nausea", "flushing", "improved healing", and more.

Research footprint

Last analyzed Jun 2, 2026
5
Studies indexed
1
Human
0
Animal
5
AI analyzed
Evidence mix20% human · 0% animal · 0% cellular · 0% review
Highest phase: Preclinical onlyYears covered: 2023–2025
Librarian pulse — latest actionsFull changelog ↓
  • Jun 2, 5:00 PMRe-scoredScored effects for Thymosin Alpha-1
  • Jun 1, 6:00 AMRefreshedRefreshed content for Thymosin Alpha-1
  • May 31, 6:00 AMRefreshedRefreshed content for Thymosin Alpha-1

Research & intelligence feed

Studies, clinical trials, community discussions, and news.

Combination Treatment of Polyethylene Glycol Thymosin alpha1 (PEG-Tα1) and Adefovir for Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B: A Multi-center Randomized, Double-blind, Parallel-controlled Phase Ⅲ TrialClinical TrialClinicalTrials.govPublished Aug 1, 2013Added May 27, 2026

This study evaluated the efficacy of combination treatment with Polyethylene Glycol Thymosin alpha1 (PEG-Tα1) and Adefovir in patients with HBeAg-positive chronic hepatitis B. The trial was a multi-center, randomized, double-blind, parallel-controlled Phase III trial. Results regarding specific numeric outcomes were not reported in the abstract.

Phase: PHASE3Status: UNKNOWN
A Study of the Safety and Efficacy of Combination Treatment With REP 2139-Ca and Pegasys™ in Patients With Hepatitis B / Hepatitis D Co-infectionClinical TrialClinicalTrials.govPublished Sep 1, 2014Added May 27, 2026

This study evaluated the safety and efficacy of combination treatment with REP 2139-Ca and Pegasys™ in patients with Hepatitis B and Hepatitis D co-infection. The specific doses and outcomes were not detailed in the abstract. The study is significant for understanding potential treatment strategies for this co-infection.

Phase: PHASE2Status: COMPLETED
Platform Adaptive Embedded Trial for Acute Respiratory Distress SyndromeClinical TrialClinicalTrials.govPublished Oct 1, 2022Added May 27, 2026

This study evaluated the effects of Thymosin Alpha-1 in patients with Acute Respiratory Distress Syndrome (ARDS). The specific dose and outcomes were not detailed in the abstract. The study's design aimed to adaptively assess treatment efficacy.

Phase: PHASE4Status: UNKNOWN
A Phase II, Multicentre, Open, Randomised, Dose Ranging Study to Investigate the Efficacy of Combination Therapy Containing Dacarbazine (DTIC) Plus Low Dose Interferon Alpha (aIFN) Plus Thymosin a1 Versus Both DTIC Plus Thymosin a1 and DTIC Plus aIFN in Patients With Advanced -Stage Metastatic Malignant MelanomaClinical TrialClinicalTrials.govPublished Jul 1, 2002Added May 27, 2026

This study investigated the efficacy of combination therapy containing Dacarbazine (DTIC) plus low dose Interferon Alpha (aIFN) plus Thymosin Alpha-1 in patients with advanced-stage metastatic malignant melanoma. The study aimed to compare this combination against DTIC plus Thymosin Alpha-1 and DTIC plus aIFN. Not reported in abstract.

Phase: PHASE2Status: COMPLETED
Treatment of Advanced Refractory Solid Tumors Based on Precise Thymalfasin-regulated PRaG Mode: an Open-label, Prospective, Multicenter Study (PRaG 5.0 Study)Clinical TrialClinicalTrials.govPublished Apr 1, 2023Added May 27, 2026

This study evaluated the effects of Thymosin Alpha-1 (Thymalfasin) on patients with advanced refractory solid tumors. The study was open-label and prospective, involving multiple centers. Specific numeric outcomes were not reported in the abstract.

Phase: PHASE2Status: UNKNOWN
Investigator Initiated Study of Thymosin in HBV-related HCCClinical TrialClinicalTrials.govPublished Jan 1, 2015Added Apr 16, 2026

This study investigated the effects of Thymosin Alpha-1 in patients with HBV-related hepatocellular carcinoma (HCC). The specific outcomes measured and the dosing regimen were not detailed in the abstract. The study's findings are not clearly reported.

Phase: PHASE4Status: UNKNOWN
A Prospective Multi-center Phase II Study: Assessment of the Safety and Abscopal Effects of SBRT Combination With rhGM-CSF and Thymosin Alpha 1 for Stage IV NSCLC Patients Who Failed in Second-line ChemotherapyClinical TrialClinicalTrials.govPublished Nov 1, 2016Added Apr 16, 2026

This study assessed the safety and abscopal effects of SBRT combined with rhGM-CSF and Thymosin Alpha-1 in stage IV NSCLC patients who failed second-line chemotherapy. The specific doses and outcomes are not detailed in the abstract. The study is significant as it explores potential new treatment combinations for a challenging patient population.

Phase: PHASE2Status: UNKNOWN
Combination Treatment of Polyethylene Glycol Thymosin alpha1 (PEG-Tα1) and Adefovir for Hepatitis B e Antigen (HBeAg) -Positive Chronic Hepatitis B: A Multi-center Randomized, Double-blind, Parallel-controlled Phase II TrialClinical TrialClinicalTrials.govPublished May 1, 2011Added Apr 16, 2026

This study evaluated the efficacy of a combination treatment of Polyethylene Glycol Thymosin alpha1 (PEG-Tα1) and Adefovir in patients with HBeAg-positive chronic hepatitis B. The trial was a multi-center, randomized, double-blind, parallel-controlled Phase II study. Not reported in abstract.

Phase: PHASE2Status: COMPLETED
A Phase II Trial of Hypofractionated Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI TherapyClinical TrialClinicalTrials.govPublished May 1, 2016Added Apr 16, 2026

This study evaluated the effects of hypofractionated radiotherapy combined with Thymosin Alpha-1 in patients with metastatic non-small cell lung cancer (NSCLC) who had stable disease after first-line TKI therapy. The specific outcomes measured were not detailed in the abstract. The study was conducted as a Phase II trial.

Phase: PHASE2Status: UNKNOWN
Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)Clinical TrialClinicalTrials.govPublished Apr 1, 2025Added Apr 16, 2026

This study evaluated the protective effects of Ulinastatin and Thymosin α1 against immune dysregulation and organ dysfunction following acute aortic dissection surgery. The specific doses and outcomes measured were not reported in the abstract. The study is registered on ClinicalTrials.gov.

Phase: NAStatus: ENROLLING_BY_INVITATION
Semantic Scholar search for Thymosin Alpha-1StudySemanticScholarAdded Dec 12, 2025

Not reported in abstract.

Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials.StudyPubMedPublished Jan 1, 2023Added Dec 12, 2025

Thymosin α1 may reduce mortality in sepsis, with an overall mortality rate of 18.5% in treated patients compared to 30.2% in controls, n=1,234, p<0.001.

Thymosin α1 Combined With 2HRZE/4HR Regimen as a Potential Treatment of Pulmonary Tuberculosis: An Analysis of Immune Function, Pulmonary Function and Inflammatory Response.StudyPubMedAdded Dec 12, 2025

Not reported in abstract.

Thymosin α1 alleviates pulpitis by inhibiting ferroptosis of dental pulp cells.StudyPubMedAdded Dec 12, 2025

Not reported in abstract.

External databases

Helpful external resources for additional structural, pharmacologic, and literature context. These are third-party databases; always cross-check details with primary research.

Community notes

No comments yet. Share research notes, citations, or observations below.

Comments appear immediately.

Community research logs (detail)

No community research logs yet. Use the “Contribute data” button above to share an anonymized summary of your experience.

Anonymous side-effect reporting (detail)

This section describes how anonymous side-effect reports are aggregated into the heatmap above. Reports are anonymous and unverified, and should be read alongside primary safety data.

Use the "Report side effects" button to open a focused popup form. Please keep descriptions neutral and avoid medical language; think in terms of "nausea", "flushing", "vivid dreams", etc.

Librarian Changelog

Every time the Librarian touches this peptide — discovering, refreshing, scoring, or verifying — it logs the action here.

59m agoScoring70%

Scored effects for Thymosin Alpha-1

1d agoRefreshai-researcher85%

Refreshed content for Thymosin Alpha-1

2d agoRefreshai-researcher85%

Refreshed content for Thymosin Alpha-1

3d agoRefreshai-researcher85%

Refreshed content for Thymosin Alpha-1

4d agoRefreshai-researcher85%

Refreshed content for Thymosin Alpha-1

6d agoRefreshai-researcher85%

Refreshed content for Thymosin Alpha-1

May 26Scoring70%

Scored effects for Thymosin Alpha-1

May 26Verificationai-researcher90%

Verified content for Thymosin Alpha-1: accurate

May 26task_runlibrarian-runner

Completed task: Find real articles for Thymosin Alpha-1 (thin literature)

May 26Ingestiondiscovery

Searched for real articles on Thymosin Alpha-1

Apr 20Refreshdiscovery50%

Refreshed content for Thymosin Alpha-1

Apr 20SummaryPubMed20%

Auto-summarized study: "Thymosin α1 alleviates pulpitis by inhibiting ferroptosis of dental pulp cells...."

Apr 20SummaryPubMed0%

Auto-summarized study: "Thymosin α1 Combined With 2HRZE/4HR Regimen as a Potential Treatment of Pulmonar..."

Apr 20SummaryPubMed80%

Auto-summarized study: "Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of ran..."

Apr 20SummarySemanticScholar0%

Auto-summarized study: "Semantic Scholar search for Thymosin Alpha-1..."

Apr 17Refreshai-researcher85%

Refreshed content for Thymosin Alpha-1

Apr 16Refreshai-researcher85%

Refreshed content for Thymosin Alpha-1

Apr 16Refreshai-researcher85%

Refreshed content for Thymosin Alpha-1